When controls and CLL were compared, the percentage of CD64+ cells was 4-fold higher (P < 0.001) in CLL patients showing marked inter-individual variability ranging from 1.2 to 93.3%. This evidence concerns the gene FCGR1A and B-cell chronic lymphocytic leukemia.